Evidence map›Paper›PMID 24916537›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2015

Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007.

Dan P Zandberg, Sandy Liu, Olga G Goloubeva, Lisa M Schumaker, Kevin J Cullen

Abstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Epidemiology of HPV Related Malignancies.Seminars in radiation oncology · 2021
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Cancer prevention research (Philadelphia, Pa.) · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Dan P ZandbergUniversity of Maryland Greenebaum Cancer Center, Baltimore, Maryland. Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Sandy LiuDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
Olga G GoloubevaUniversity of Maryland Greenebaum Cancer Center, Baltimore, Maryland.
Lisa M SchumakerUniversity of Maryland Greenebaum Cancer Center, Baltimore, Maryland.
Kevin J CullenUniversity of Maryland Greenebaum Cancer Center, Baltimore, Maryland. Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland. kcullen@umm.edu.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
UMGCC Paul Calabresi Clinical Oncology Training ProgramK12CA126849 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI SAUSVILLE, EDWARD A. · 2008 to 2013
$4.0M
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAMK12CA076903 · NCI · GEORGETOWN UNIVERSITY · PI CULLEN, KEVIN J · 1997 to 2002
$1.0M
NCI NIH HHS 1 P30 CA 134274-01NCI NIH HHS K12 CA076903NCI NIH HHS K12 CA126849NCI NIH HHS P30 CA134274
6 · The paper itself

Abstract

While we previously reported a striking racial difference in the prevalence of human papilloma virus (HPV)-positive squamous cell carcinoma of the oropharynx (OPSCC), less is known about differences in outcomes and trends over time in OPSCC by HPV status and race. We conducted a retrospective analysis of 467 patients with OPSCC treated at the University of Maryland Greenebaum Cancer Center (Baltimore, MD) between 1992 and 2007, of which 200 had tissue available for HPV16 testing. HPV16-positive patients were significantly more likely to be white, with 45.5% of whites and 15.5% of blacks testing positive for HPV16. There was a significant increase in HPV16-positive OPSCC for all patients over time from 15.6% in 1992 to 1995 to 43.3% in 2004 to 2007 (P = 0.01). From 1992 to 1995, 33% of white patients were HPV16-positive, with no black patients positive. From 2004 to 2007, 17.7% of black patients and 54% of white patients were HPV16-positive. White and black patients with HPV16-positive tumors had an identical and favorable overall survival (OS; median, 8.1 and 8.1 years, respectively). However, among HPV16-negative patients, whites had an improved OS compared with blacks (median, 2.3 vs. 0.9 years, respectively; P = 0.02), including when analyzed in a multivariable Cox regression model. From 1992 to 2007, the percentage of HPV16-positive OPSCC increased for white patients and was seen for the first time in black patients. While survival for HPV-positive black and white patients was similar and favorable, outcomes for HPV-negative patients were poor, with blacks having worse survival even after controlling for baseline characteristics.

Indexed as

Human papillomavirus 16Academic Medical CentersAdultAgedAged, 80 and overBlack or African AmericanCarcinoma, Squamous CellEthnicityFemaleHumansKaplan-Meier EstimateMaleMarylandMiddle AgedOropharyngeal NeoplasmsPapillomavirus Infections

Identifiers

PMID24916537
PMCPMC4429293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.